All In Biotech

Drug Trial Radar · NCT00811954

Comparative Study of Three NNRTI-Sparing HAART Regimens

The ARDENT Study: Atazanavir, Raltegravir, or Darunavir With Emtricitabine/Tenofovir for Naive Treatment

Last checked: Nov 19, 2026Latest source record: Sep 5, 2014 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 1,814 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,814

Actual

Start

May 2009

Primary completion

Jun 2013

Study completion Jun 2013

Sponsor

Sponsor type
Research network
Collaborators
National Institute of Allergy and Infectious Diseases (NIAID); Bristol-Myers Squibb; Gilead Sciences; Merck Sharp & Dohme LLC; Tibotec Therapeutics, a Division of Ortho Biotech Products, L.P., USA
First posted
Dec 19, 2008

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The U.S. Department of Health and Human Services (HHS) guidelines recommend that HIV infected patients who have never received anti-HIV therapy be treated with a triple drug regimen. The most commonly prescribed and successful regimen contains the medication efavirenz (EFV). However, this regimen may not be an option for everyone, hence alternative regimens are needed. This study was designed to look at how well different combinations of anti-HIV drugs work to decrease the amount of HIV in the blood (viral load) of and allow immune system recovery in people who have never received anti-HIV therapy. This study also examined drug tolerability and safety for the various drug combinations.

Conditions

  • HIV Infection

Interventions

  • Emtricitabine/tenofovir disoproxil fumarateDrug

    200 mg emtricitabine/300 mg tenofovir disoproxil fumarate taken orally daily. A combination drug of two nucleoside reverse transcriptase inhibitors (NRTIs).

  • RaltegravirDrug

    400 mg taken orally twice daily. An integrase inhibitor (INI).

  • DarunavirDrug

    800 mg taken orally once daily. A protease inhibitor (PI).

  • RitonavirDrug

    100 mg taken orally once daily. A protease inhibitor (PI).

  • AtazanavirDrug

    300 mg taken orally once daily. A protease inhibitor (PI).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Cumulative Probability of First Virologic Failure by Week 96Time frame: From study entry to week 96
  2. Cumulative Incidence of Discontinuation of the RAL or PI Component of Randomized Treatment for Toxicity by Week 96Time frame: From study entry to week 96

Locations

57 sites in 2 countries. Site status is shown where the registry gives one.

  • Alabama Therapeutics CRS

    Birmingham, Alabama

  • Miller Children's Hospital

    Long Beach, California

  • USC CRS

    Los Angeles, California

  • UCLA CARE Center CRS

    Los Angeles, California

  • Stanford CRS

    Palo Alto, California

  • Ucsd, Avrc Crs

    San Diego, California

  • Ucsf Aids Crs

    San Francisco, California

  • Harbor-UCLA Med. Ctr. CRS

    Torrance, California

  • University of Colorado Hospital CRS

    Aurora, Colorado

  • Denver Public Health CRS

    Denver, Colorado

  • Georgetown University CRS (GU CRS)

    Washington D.C., District of Columbia

  • Howard Univ. Washington DC NICHD CRS

    Washington D.C., District of Columbia

  • South Florida Childrens Diagnostic & Treatment Cen (5055)

    Fort Lauderdale, Florida

  • University of Florida Jacksonville (5051)

    Jacksonville, Florida

  • Univ. of Miami AIDS CRS

    Miami, Florida

  • The Ponce de Leon Center CRS

    Atlanta, Georgia

  • Northwestern University CRS

    Chicago, Illinois

  • Rush Univ. Med. Ctr. ACTG CRS

    Chicago, Illinois

  • Tulane University New Orleans NICHD CRS (5095)

    New Orleans, Louisiana

  • IHV Baltimore Treatment CRS

    Baltimore, Maryland

  • Johns Hopkins Adult AIDS CRS

    Baltimore, Maryland

  • Massachusetts General Hospital CRS

    Boston, Massachusetts

  • Brigham and Women's Hosp. ACTG CRS

    Boston, Massachusetts

  • Bmc Actg Crs

    Boston, Massachusetts

  • Beth Israel Deaconess Med. Ctr., ACTG CRS

    Boston, Massachusetts

  • Wayne State Univ. CRS

    Detroit, Michigan

  • Henry Ford Hosp. CRS

    Detroit, Michigan

  • Washington U CRS

    St Louis, Missouri

  • Cooper Univ. Hosp. CRS

    Camden, New Jersey

  • New Jersey Medical School- Adult Clinical Research Ctr. CRS

    Newark, New Jersey

  • Cornell CRS

    New York, New York

  • NY Univ. HIV/AIDS CRS

    New York, New York

  • Metropolitan Hospital

    New York, New York

  • HIV Prevention & Treatment CRS

    New York, New York

  • AIDS Care CRS

    Rochester, New York

  • Univ. of Rochester ACTG CRS

    Rochester, New York

  • SUNY Stony Brook NICHD CRS (5040)

    Stony Brook, New York

  • Bronx-Lebanon Hosp. Ctr. CRS

    The Bronx, New York

  • Unc Aids Crs

    Chapel Hill, North Carolina

  • Duke Univ. Med. Ctr. Adult CRS

    Durham, North Carolina

Showing 40 of 57 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.